期刊文献+

缬沙坦、苯那普利、非洛地平治疗高血压左室肥厚 被引量:10

Comparison of Efficacy of Valsartan,Benazepril and Felodipine on Left Ventricular Hypertrophy in Essential Hypertension and Aldosterone Escape During Therapy
下载PDF
导出
摘要 目的研究缬沙坦、苯那普利、非洛地平的降压效果,对高血压左室肥厚(LVH)的逆转作用并观察治疗中的醛固酮(Ald)逃逸现象与LVH关系。方法入选高血压左室肥厚患者111例随机分成服用缬沙坦组(36例)或苯那普利组(39例)或非洛地平组(36例),监测治疗过程中的血压变化及服药10~14周、20~26周时血浆血管紧张素Ⅱ(AngⅡ)、醛固酮(Ald)变化,治疗前后超声心动图检查及检测血尿常规、血糖、血脂、肝肾功能检查,记录药物不良反应。结果3组均能有效降压,效果相当(组内治疗前后比较,P<0.01,组间比较,P>0.05)。缬沙坦组、苯那普利组均能逆转LVH。左室质量(LVM)、左室质量指数(LVMI)下降(组内治疗前后比较P<0.01;组间P>0.05),舒张功能改善,二尖瓣血流舒张早期与晚期最大流速比值(E/A)升高(组内治疗前后比较,P<0.01;组间比较,P>0.05);非洛地平组虽有LVM下降(P<0.05),但LVMI、E/A无明显变化(P>0.05)。缬沙坦组治疗后AngⅡ显著上升(P<0.01);苯那普利组治疗10~14周AngⅡ明显下降(P<0.01),20~26周Ald升高,接近治疗前水平(P>0.05),与10~14周比较明显升高(P<0.01);非洛地平组AngⅡ较治疗前显著上升(P<0.01)。缬沙坦组治疗后Ald浓度明显下降(P<0.01)。苯那普利组Ald逃逸发生率36%,有逃逸者LVH逆转较差。结论缬沙坦、苯那普利、非洛地平降压效果相当。3组对LVH均有逆转作用。缬沙坦、苯那普利作用优于非洛地平。缬沙坦长期应用无Ald逃逸。非洛地平治疗期间对血浆Ald无明显影响。  Objective To compare the efficacy of valsartan,benazepril and felodipine on reversal of left ventricular hypertrophy(LVH)in patients with hypertension and the relevant "aldosterone escape phenomena".Methods One hundred eleven patients with hypertension-related LVH were randomly to receive valsartan(80-160 mg/d,n=36),benazepril(10-20 mg/d,n=39)and felodipine(5 mg/d,n=36).Plasma angiotensin Ⅱ(Ang Ⅱ)and aldosterone(Ald)were determined before and 10-14 weeks 20-26 weeks after treatment.Echocardiographic examinations and blood routine,urine routine,blood glucose,blood lipid,liver function and renal function were conducted in all subjects before and after treatment.Results Blood pressure was significantly decreased in all three groups(P〈0.01)with no defferences was found among them.Both valsartan treatment group and benazepril treatment reversed LVH;reduced left ventricular mass(LVM)and left ventricular mass index(LVMI)(P〈0.01)and increased E/A ratio(P〈0.01);while felodipine only decreased LVM(P〈0.05)with no changes in LVMI and E/A ratio(P〉0.05).Valsartan increased plasma Ang Ⅱ at 10-14 weeks and furthermore at 20-26 weeks;benazepril decreased plasma Ang Ⅱ initiatively with trend of rebound at 20-26 weeks;however,plasma Ang Ⅱ was kept constantly in felodipine group.Valsartan decreased Ald and sustained during the all treatment period.On contrary,benazepril initiatively decreased Ald which was rebound to baseline level at 20-26 weeks.No change in Ald by felodipine was found during the treatment.After treatment plasma Ald level was significantly related to the reduction of LVH in both valsartan and benazepril groups.36% patients in benazepril group was found to have "aldosterone escape".Conclusion The antihypertensive effect was similar between valsartan,benazepril and felodipine.Although three medications all reversed LVH,but valsartan,benazepril was more effective than felodipine.There was no evidence of aldosterone escape in the long-term treatment with valsartan.Valsartan might have more advantages in reversal of LVH than benazepril.Felodipine had no effect on the plasma level of aldosterone.
出处 《中华高血压杂志》 CAS CSCD 北大核心 2007年第8期641-644,共4页 Chinese Journal of Hypertension
关键词 缬沙坦 苯那普利 非洛地平 左室肥厚 醛固酮逃逸 Valsartan Benazepril Felodipine Essential hypertension Left Ventricular Hypertrophy Aldosterone escape
  • 相关文献

参考文献8

  • 1[1]Kiyoshi M,Koji F,Hideyuki O,et al.Role of aldosterone in left ventricular hypertrophy in hypertension[J].AJH,2006,19:13-18.
  • 2徐瑞,张运,张梅,李秀昌,蔡恒,陈文强,朱慧,葛志明,张薇.氯沙坦和雷米普利单用及合用对高血压大鼠左室重构和功能的影响[J].中华医学杂志,2005,85(45):3199-3204. 被引量:7
  • 3陈浩.依那普利和非洛地平对高血压左室肥厚的疗效比较[J].中国动脉硬化杂志,2001,9(2):159-160. 被引量:1
  • 4张昀昀,顾水明,薛晓培,张洁,魏盟.伊贝沙坦能改善高血压病人左室肥厚和胰岛素抵抗[J].中华高血压杂志,2006,14(8):664-666. 被引量:8
  • 5[5]Malmqvist K,Kahan T,Edner M,et al.Regression of left ventricular hypertrophy in human hypertension with irbesartan[J].J Hypertens,2001,19:1167-1176.
  • 6[6]Devereux RB,Alonso DR,Lutas EM,et al.Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy findings[J].Am J Cardiol,1986,57:450-458.
  • 7[7]Devereux RB,Casale PN,Kligfield P,et al.Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension,mitral regurgitation and dilated cardiomyopathy[J].Am J Cardiol,1986,57:1388-1393.
  • 8[8]Sato A,Saruta T.Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy[J].J Int Med Res,2001,29:13-21.

二级参考文献30

  • 1[3]Malmqvist K,Kahan T,Edner M,et al.Regression of left ventricular hypertrophy in human hypertension with irbesartan[J].J Hypertens,2001,19:1167-1176.
  • 2[4]Ikeda Y,Nakamura T,Takano H,et al.Angiotensin Ⅱ-induced cardiomyocytes hypertrophy and cardiac fibrosis in strokeprone spontaneously hypertensive rats[J].J Lab Clin Med,2000,135:353-359.
  • 3[5]Shikata C,Takeda A,Takeda N.Effect of an ACE inhibitor and an AT1 receptor antagonist on cardiac hypertrophy[J].Mol Cell Biochem,2003,248:197-202.
  • 4[6]Seccia TM,Belloni AS,Kreutz R,et al.Cardiac fibrosis occurs early and involves endothelin and AT1 receptors in hypertension due to endogenous angiotensin Ⅱ[J].J Am Coll Cardiol,2003,41:666-673.
  • 5[7]Matsui T,Nagoshi T,Rosenzweig A.Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival[J].Cell Cycle,2003,2:220-223.
  • 6[8]Kohno M,Minami M,Kano H,et al.Effect of angiotensinconverting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensives with left ventricular hypertrophy[J].Metabolism,2000,49:1356-1360.
  • 7邓珏琳,中华心血管病杂志,1994年,27卷,8期,127页
  • 8Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 2001, 345: 1667-1675.
  • 9McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 2003, 362: 767-771.
  • 10Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 2003, 362: 777-781.

共引文献13

同被引文献117

引证文献10

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部